Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Johnson & Johnson’s Tecvayli delivers superior survival outcomes in blood cancer trial

Johnson & Johnson (NYSE:JNJ) reported positive late-stage clinical data for its blood cancer therapy Tecvayli (teclistamab-cqyv), demonstrating significant improvements in survival metrics for patients with relapsed or refractory multiple myeloma.

Leia mais: Johnson & Johnson’s Tecvayli delivers superior survival outcomes in blood cancer trial
Grafa

Bristol Myers drug halves risk of myeloma progression in pivotal trial

Bristol Myers Squibb (NYSE:BMY) announced positive late-breaking results from its Phase 3 SUCCESSOR-2 clinical trial, demonstrating that its experimental oral therapy mezigdomide significantly extends the time patients with relapsed or refractory multiple myeloma live without their disease worsening.

Leia mais: Bristol Myers drug halves risk of myeloma progression in pivotal trial
Grafa

Pfizer’s Lorbrena shows historic seven-year survival advantage in lung cancer trial

Pfizer (NYSE:PFE) announced unprecedented seven-year follow-up results from its Phase 3 CROWN trial, revealing that its oncology drug Lorbrena significantly extended progression-free survival in patients with a specific, aggressive form of lung cancer.

Leia mais: Pfizer’s Lorbrena shows historic seven-year survival advantage in lung cancer trial